Ailomics Therapeutics is a pharmaceutical R&D startup with a pioneering computational and experimental platform to discover novel targets and develop efficacious therapeutics for the diseases of significant unmet medical needs.
Ailomics Therapeutics leverages patients-derived omics data and AI-augmented bioinformatics analytics to deeply understand disease biology and identify the targets that drive disease progressions.
Learning from human disease biology, Ailomics Therapeutics develops high-translatability disease models to screen for and optimize functional molecules for therapeutic interventions.
The human disease biology insights also enable Ailomics Therapeutics to discover high-precision biomarkers for patient stratification in clinical trials.
Company Details
- Employees
- 9
- Founded
- -
- Address
- 1077 Zhangheng Road, Pudong,shanghai,china
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.ailomics.com
- HQ
- PuDong, Shanghai
Ailomics Therapeutics Questions
Ailomics Therapeutics's website is https://www.ailomics.com
Ailomics Therapeutics's LinkedIn profile is https://cn.linkedin.com/company/ailomics
Ailomics Therapeutics has
9 employees.
View email and phone details for 9
employees at Ailomics Therapeutics.
Ailomics Therapeutics's industry is
Biotechnology Research
Ailomics Therapeutics's top competitors are
Tentarix Biotherapeutics,
Boomray Pharmaceuticals,
Glycomantra,
Icardiooncology 三度医学,
Fibrogen, Inc.,
Smartnuclide Biopharma,
Sherlock Biosciences,
Gni Group Ltd.,
Xaira Therapeutics,
Pspro.
Ailomics Therapeutics's categories are Biotechnology Research
Ailomics Therapeutics's founding year is 2022
